Entries |
Document | Title | Date |
20100279943 | CYTOPLASMIC MALATE DEHYDROGENASE (MDH1) TARGETED TREATMENT FOR NEURODEGENERATIVE DISEASES - The present invention provides compositions for treating neurodegenerative diseases, including ALS, involving complex formation of cytosolic malate dehydrogenase with certain neurodegenerative disease-causing proteins, comprising an agent capable of reducing an interaction between a malate dehydrogenase protein and a conformationally altered or mutant protein associated with a neurodegenerative disorder, including mutant SOD1 protein. The present invention also provides methods of identifying an agent capable of treating such disorders, including ALS, comprising testing agents for the ability to disrupt or prevent formation of a malate dehydrogenase complex with a conformationally altered or mutant protein associated with a neurodegenerative disorder, including MDH-mutant-SOD1 complex, and methods of treating neurodegenerative disorders. | 11-04-2010 |
20100292157 | Combination Treatments for Alzheimer's Disease and Similar Diseases - The invention relates generally to novel compositions and methods comprising a cyclohexanehexol and a secretase inhibitor. The compositions and methods provide beneficial effects, in particular sustained beneficial effects, in the treatment of diseases involving a disorder in protein folding and/or aggregation, and/or amyloid formation, deposition, accumulation, or persistence, such as Alzheimer's disease and related neurodegenerative disorders. | 11-18-2010 |
20110015131 | METHODS FOR PREVENTING AND TREATING ALZHEIMER'S DISEASE (AD) - The present invention relates to methods for preventing Alzheimer's disease (AD) with an Aβ42 mimotope and binds to an antibody specific for DAEFRH (SEQ ID NO: 1) which is a part of the naturally-occurring Aβ42 sequence. | 01-20-2011 |
20110039786 | METASTIN DERIVATIVE AND USE THEREOF - The present invention provides a metastin derivative represented by the formula (I): | 02-17-2011 |
20110053858 | HETEROCYCLIC PEPTIDE KETOAMIDES - A novel class of peptide α-ketoamides useful for selectively inhibiting calpains, selectively inhibiting cysteine proteases, and generally inhibiting all cysteine proteases, having the formula M-AA | 03-03-2011 |
20110065645 | Compositions and Methods for Modulating Neuron Degeneration and Neuron Guidance - Methods for inhibiting degeneration of a neuron, methods of treating a neurodegenerative disease, methods for promoting degeneration of a neuron are provided, methods for modulating neuron cell guidance of a neuron, as well as compounds useful in the methods of the invention, such as a Wnt compound, a Fzd3 dephosphorylating agent, a Fzd3 phosphorylating agent, or a SHH compound as disclosed herein. | 03-17-2011 |
20110071088 | METHOD FOR TREATING NEUROLOGICAL DISORDERS - The present invention is based on the discovery that suppressing the activity of the Nogo receptor (NgR) alone does not result in extensive axon regeneration unless the intrinsic growth program of neurons is also activated. Accordingly, the present invention is directed to methods of stimulating axon regeneration using a combination therapy wherein agents that inhibit NgR activity or downstream pathways activated by inhibitory signals are combined with agents that activate the growth pathway of neurons (e.g. polypeptide growth factors, activators of macrophages, purine nucleosides, or hexoses). | 03-24-2011 |
20110098227 | Soluble notch-based substrates for gamma secretase and methods and compositions for using same - The present invention is directed to novel soluble substrates for γ-secretase. More particularly, the invention provides a soluble fusion polypeptide with a Notch segment containing the γ-secretase-dependent cleavage sites (γ and ε) fused to a NusA protein. Methods and compositions for making and using such a fusion protein are disclosed. | 04-28-2011 |
20110105404 | Beta Sheet Inhibiting Peptides For Preventing And/Or Treating Alzheimer`s Disease - Provided are β-sheet breaker peptides binding to β amyloid peptide (Aβ1-42), which have the homologous sequence with Aβ 14-23. β-sheet breaker peptides can be used for the manufacture of a medicament for prophylactic and/or therapeutic treatment of Alzheimer's Disease. | 05-05-2011 |
20110112034 | Modulation of synaptogenesis - Soluble proteins, e.g. thrombospondins, can trigger synapse formation. Such proteins are synthesized in vitro and in vivo by astrocytes, which therefore have a role in synaptogenesis. These thrombospondins are only expressed in the normal brain exactly during the period of developmental synaptogenesis, being off in embryonic brain and adult brain but on at high levels in postnatal brain. Methods are provided for protecting or treating an individual suffering from adverse effects of deficits in synaptogenesis, or from undesirably active synaptogenesis. These findings have broad implications for a variety of clinical conditions, including traumatic brain injury, epilepsy, and other conditions where synapses fail to form or form inappropriately. Synaptogenesis is enhanced by contacting neurons with agents that are specific agonists or antagonists of thrombospondins. Conversely, synaptogenesis is inhibited by contacting neurons with inhibitors or antagonists of thrombospondins. | 05-12-2011 |
20110112035 | THERAPEUTIC USE OF A GROWTH FACTOR, METRNL - The present invention relates to the field of therapeutic use of proteins, genes and cells, in particular to the therapy based on the biological function of a secreted therapeutic protein, METRNL, in particular for the treatment of disorders of the nervous system. METRNL is a Nerve Survival and Growth factor with neuroprotective and/or neurogenesis effects. | 05-12-2011 |
20110144029 | Model Systems and Materials for the Study and Treatment of Neurodegenerative Diseases - The present invention provides models for studying the development of, and/or pathologies associated with neurodegenerative diseases, and agents that can modulate such development and/or pathologies. | 06-16-2011 |
20110160140 | COMPOSITION FOR IMPROVING BRAIN FUNCTION AND METHOD FOR IMPROVING BRAIN FUNCTION - The present invention provides a composition which may be ingested orally in a small dose for the purpose of improving brain function, and a method for improving brain function. The present invention is a composition for improving brain function, the composition comprising, as an active ingredient, Xaa-Pro-Pro (wherein Xaa represents Ile, Leu or Ser). | 06-30-2011 |
20110160141 | Neurotrophic Peptides - The present invention relates to a neurotrophic peptide having an amino acid sequence of VGDGGLFEKKL (SEQ ID NO:1), EDQQVHFTPTEG (SEQ ID NO:2) or IPENEADGMPATV (SEQ ID NO:3), and comprising an adamantyl group at the C- and/or N-terminal end. | 06-30-2011 |
20110166074 | CLN2 TREATMENT OF ALZHEIMER'S DISEASE - A method of treating Alzheimer's Disease may include administering to a subject in need of such treatment a CLN2 therapeutic having beta-amyloid degradation activity. | 07-07-2011 |
20110166075 | METHOD OF TREATING DEGENERATIVE DISORDERS OF THE NERVOUS SYSTEM BY ADMINISTRATION OF FIBRINOGEN FRAGMENT - The invention herein related to methods and compositions for treating nervous system disorders. The methods comprise peptides that bind to receptors important in disease progression, thus attenuating the disease. | 07-07-2011 |
20110178023 | Use Of SCO-Spondin Peptides For Inhibiting Or Preventing Neuronal Apoptosis Mediated By Cell Death Receptor Ligands - The invention relates to a polypeptide derived from the TSR (thrombospondin type 1 units) of SCO-Spondin for inhibiting or preventing the apoptosis mediated by the cell death receptor ligands, such as TRAIL or FasL. The polypeptide of the invention comprises a sequence -W-S-A1-C-S-A2-C-G- wherein A1 and A2 are amino acid sequences comprising 1 to 5 amino acids. More particularly, the invention relates to said polypeptide for inhibiting or preventing the apoptosis associated with a disease selected from the group consisting of neurodegenerative disorders, cerebral ischemia, neuronal traumas, neuronal inflammatory diseases, and viral neurodegenerations. | 07-21-2011 |
20110178024 | AMYLOID BETA-PEPTIDES AND METHODS OF USE THEREOF - The present invention relates to polypeptides, compositions, and methods of use thereof for optimized treatment of diseases or disorders associated with amyloid beta protein (Aβ) accumulation in a subject. This invention also relates to polypeptides, compositions, and methods of use thereof for optimized immunization against diseases characterized by Aβ accumulation in a subject. This invention further relates to pharmaceutical formulations comprising these polypeptides and methods of use for administering to a subject an optimized Aβ peptide that elicits a beneficial T cell response; for example, a T cell response reducing Aβ accumulation in the brain of a subject, without causing an encephalitic response. | 07-21-2011 |
20110183912 | AGENT FOR PROMOTING NEURONAL DIFFERENTIATION AND METHOD THEREFOR - An agent for promoting neuronal differentiation of a neural stem/progenitor cell includes an inhibitor of function of a COUP-TFI protein and/or a COUP-TFII protein. To promote neuronal differentiation of a neural stem/progenitor cell, the agent is administered to the neural stem/progenitor cell to inhibit function of a COUP-TFI protein and/or a COUP-TFII protein. | 07-28-2011 |
20110190217 | METHODS FOR TREATING INFLAMMATORY DISORDERS AND TRAUMATIC BRAIN INJURY USING STABILIZED NON-HEMATOPOIETIC EPO SHORT PEPTIDES - The described invention provides methods for treating an inflammatory brain disease, disorder or condition and for treating a traumatic brain injury having an inflammatory component in a subject in need thereof using isolated erythropoietin (EPO)-derived oligopeptides. | 08-04-2011 |
20110201557 | METHODS AND COMPOSITIONS FOR TREATING NEURODEGENERATIVE DISORDERS AND ALZHEIMER'S DISEASE AND IMPROVING NORMAL MEMORY - The disclosure relates generally to neurodegenerative disorders and more specifically to a group of presenilin/G-protein/c-src binding polypeptides and methods of use for modulating signaling and progression of Alzheimer's disease. | 08-18-2011 |
20110201558 | Anaplerotic Therapy for Alzheimer's Disease and the Aging Brain - The present invention describes methods and compositions for the treatment of neurodegenerative conditions including Alzheimer's disease (AD) and aging. The present invention discloses an anaplerotic diet therapy for the treatment of AD. The high fat, low carbohydrate diet described in the various embodiments of the present invention increasing circulating ketone bodies, reduces amyloid-β (Aβ) deposition in AD patients, thereby improving cognition and locomotive skills. | 08-18-2011 |
20110212896 | PEPTIDES FOR THE TREATMENT OF OXIDATIVE STRESS RELATED DISORDERS - Isolated DJ-1 related peptides are disclosed and pharmaceutical compositions comprising same for treating oxidative stress-related disorder. | 09-01-2011 |
20110218152 | COMPOUNDS FOR STIMULATING P-GLYCOPROTEIN FUNCTION AND USES THEREOF - The present invention is directed to polypeptides (e.g., fragments) derived from P-glycoprotein and caveolin-1 which are capable of inhibiting the interaction between these two proteins. Inhibition of this interaction leads to increase of efflux of compounds that are transported by P-gp. The invention further includes methods of treating patients having diseases that benefit from increased P-gp-mediated efflux. Such diseases include neoplasms such as cancer and neurological diseases such as neurodegenerative diseases. | 09-08-2011 |
20110245180 | Modified Peptide that reduces pain in peripheral neuropathy - Chemokine signaling is important in neuropathic pain, with microglial cells expressing CCR2 playing a well established key role. DAPTA, a gp120-derived CCR5 entry-inhibitor has been shown to inhibit CCR5-mediated monocyte migration and to attenuate neuroinflammation. We disclose here that as a stabilized analog of DAPTA, the short peptide All D TTNYT exhibits potent antagonism for both CCR2 (IC | 10-06-2011 |
20110251132 | TREATMENT WITH A PHARMACEUTICAL COMPOSITION COMPRISING MANF2 NUCLEIC ACID - A method for treating a condition in a patient, wherein the condition is selected from the group consisting of Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, stroke and peripheral neuropathy. The method consists of administering to the patient a pharmaceutically effective amount of a pharmaceutical composition comprising the MANF2 polypeptide of SEQ ID NO:2 or a functional fragment thereof. | 10-13-2011 |
20110269689 | HIGH PENETRATION COMPOSITIONS AND THEIR APPLICATIONS - High penetration compositions (HPC) of a parent compound, which are capable of crossing biological barriers with high penetration efficiency. The HPCs are capable of being converted to parent drugs or parent drug-related compounds such as metabolites after crossing one or more biological barriers and thus can render treatments for the conditions that the parent drugs or parent drug-related compounds can. Additionally, the HPCs are capable of reaching areas that their parent drugs or parent drug-related compounds may not be able to access or to render a sufficient concentration at the target areas HPCs of NSAIA, for example, have demonstrated indications such as treating hair loss. A HPC can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate. | 11-03-2011 |
20110281804 | PEPTIDIC AND PEPTIDOMIMETIC COMPOUNDS FOR REGULATING AUTOPHAGY - The present invention relates to peptides, peptidomimetic compounds and pharmaceutical uses thereof for the treatment of neurodegenerative diseases or tumourigenesis and more specifically diseases deriving from the dysregulation of the signalling system of Ambra-1-mediated autophagy. | 11-17-2011 |
20110294741 | USE OF COMPOUNDS IN THE TREATMENT OF TAU-INDUCED CYTOTOXICITIES - The present invention relates to derivatives of L-Tyrosyl-L-Arginine and the use of said derivatives in the prevention and/or treatment of a tau-induced cytotoxicity. | 12-01-2011 |
20110306557 | NEURAL REGENERATION PEPTIDES AND METHODS FOR THEIR USE IN TREATMENT OF BRAIN DAMAGE - The invention discloses a family of neuronal migration-inducing, proliferation-promoting and neurite outgrowth promoting factors, termed NRP compounds, and provides compositions and methods for the use of NRP compounds in the treatment of brain injury and neurodegenerative disease. NRP-1 compounds induce neurons and neuroblasts to proliferate and migrate into areas of damage caused by acute brain injury or chronic neurodegenerative disease, such as stroke, trauma, nervous system infections, demyelinating diseases, dementias, and metabolic disorders. NRP compounds may be administered directly to a subject or to a subject's cells by a variety of means including orally, intraperitoneally, intravascularly, and directly into the nervous system of a patient. | 12-15-2011 |
20110306558 | PROSAPOSIN AS A NEUROTROPHIC FACTOR - Prosaposin, saposin C and various peptide fragments of saposin C stimulate neurite outgrowth in vitro. In addition, prosaposin and saposin C promote increased myelination ex vivo. Prosaposin is present in large neurons of the brain, including both upper and lower motor neurons. | 12-15-2011 |
20110312895 | DIPEPTIDE MIMETICS OF NGF AND BDNF NEUROTROPHINS - The invention relates to compounds having either agonist or antagonist activities for the neurotrophins NGF and BDNF and represented by monomeric or dimeric substituted dipeptides that are analogs of the exposed portions of loop 1 or loop 4 regions of these neurotrophins near or at a beta-turn of the respective loop. N-acylated substituents of these dipeptides are biostereoisomers of the amino acid residues preceding these dipeptide sequences in the neurotrophin primary structure. The dimeric structure is produced advantageously by using hexamethylenediamine to which dipeptides are attached via their carboxyl groups. The claimed compounds displayed neuroprotective and differentiation-inducing activities in cellular models and enhanced the amount of phosphorylated tyrosine kinase A and the heat shock proteins Hsp32 and Hsp70 in the concentration range of 10 | 12-22-2011 |
20110319334 | COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF NEURODEGENERATIVE DISEASES - Isolated peptides are provided, being less than 20 amino acids in length. The peptides comprising an amino acid sequence GVLYVGSKTREGV (SEQ ID NO: 12) AAATGLVKREE (SEQ ID NO: 13) or GVVAAAEKTKQG (SEQ ID NO: 14), mimetics and/or fragment thereof, the peptides being capable of inhibiting alpha synuclein aggregation. Pharmaceutical compositions comprising same are also provided as well as uses thereof. | 12-29-2011 |
20120010148 | COMBINATION THERAPIES USING NAP - This invention relates to treatment of neurodegeneration, multiple sclerosis, or schizophrenia using an ADNF III polypeptide in combination with another therapeutic agent. Neurodegeneration, including neurodegeneration caused by dementia-related conditions, such as tauopathies, including Alzheimer's disease, and aging-related dementia, is treated by a combination of an ADNF III polypeptide and an acetylcholinesterase inhibitor. Multiple sclerosis is treated by a combination of an ADNF III polypeptide and glatiramer acetate. Schizophrenia is treated with a combination of an ADNF III peptide and an antipsychotic drug, selected from Aripiprazole, Clozapine, Ziprasidone, Resperidone, Quetiapine, and Olanzapine. | 01-12-2012 |
20120015885 | COMPOSITIONS AND METHODS FOR CaMKII INHIBITORS AND USES THEREOF - Embodiments herein generally relate to methods, compositions and uses of CaMKII inhibitors. Other embodiments relate to methods, compositions and uses of agents that target CaMKII. Yet further embodiments relate to compositions, methods and uses of CaMKIIN-derived molecules and other CaMKII inhibitor molecules that inhibit autonomous CaMKII activity. In accordance with these embodiments, compositions that inhibit autonomous CaMKII activity may be used for treating conditions causing neuronal cell death, for treating cancer or for treating neurodegenerative disorders. | 01-19-2012 |
20120021992 | METHODS FOR IMPROVING NEUROLOGICAL OUTCOME AFTER NEURAL INJURY AND NEURODEGENERATIVE DISEASE - Thymosin β | 01-26-2012 |
20120115790 | THERAPEUTIC APPROACH TO NEURODEGENERATIVE DISORDERS USING A TFP5-PEPTIDE - Disclosed herein are isolated peptides, pharmaceutical compositions and methods for use of such for treating subjects with a neurodegenerative disease, such as Alzheimer's. In an example, an isolated polypeptide includes a cyclin dependent kinase 5 (Cdk5) inhibitory domain that has at least 95% sequence identity to the amino acid sequence set forth as SEQ ID NO: 1, wherein the Cdk5 inhibitory domain is linked to a protein transduction domain. Methods of reducing or inhibiting one or more symptoms associated with a neurodegenerative disease by administering a therapeutically effective amount of a pharmaceutical composition including one or more disclosed peptides are also provided. | 05-10-2012 |
20120115791 | Methods for Treating Immune Mediated Neurological Diseases - Polypeptides and other compounds that can bind specifically to the C | 05-10-2012 |
20120122794 | Compound And Method For Treatment Of Alzheimer's Disease - An isolated protein selected from the group consisting of (i) proteins comprising an amino acid sequence having at least 70% identity to the C-terminal domain of lung surfactant protein C precursor (CTproSP-C, “CTC”) from a mammal; and (ii) proteins comprising an amino acid sequence having at least 70% identity to the Brichos domain of CTproSP-C from a mammal, is disclosed for treatment of Alzheimer's disease in a mammal, including man. | 05-17-2012 |
20120122795 | ACCELERATED EXTENSION OF AXONS - The present disclosure relates to methods and compositions for promoting the extension of a neural cell by increasing the expression of activity of cofilin in the cell. The increase can be local to the end of the neural cell in need of extension and the neural cell can be a cell in an individual. By extending the neural cell to reach its synaptic target, the methods and compositions of the present disclosure can also be used for treating neurological diseases characterized by damaged or degenerated neurons. | 05-17-2012 |
20120129782 | Inhibition of ApoE Cleavage Activity in the Treatment of ApoE-Related Disorders - The present invention provides methods for treating apoE-related disorders. The methods generally involve administering an effective amount of an agent that inhibits activity of an enzyme that cleaves apoE. | 05-24-2012 |
20120142604 | NOVEL APPLICATIONS OF HIP/PAP OR DERIVATIVES THEREOF - The use of the HIP/PAP protein or a protein derivative thereof for manufacturing a medicament for preventing or treating:
| 06-07-2012 |
20120149646 | LONG TERM POTENTIATION WITH CYCLIC-GLUR6 ANALOGS - This invention discloses CN2097-like compositions that facilitate the induction of long-term potentiation (LTP). In one embodiment the method comprises inducing long-term potentiation in a subject by the method of administering a therapeutically effective dose of a CN2907-like compound. | 06-14-2012 |
20120190626 | AMYLOID BETA FIBRILLOGENESIS-INHIBITING PEPTIDE - The present invention provides a peptide which functions as a mimic peptide of an amyloid β peptide and is capable of inhibiting the fibrillogenesis of an amyloid β peptide. The present invention relates to an 8- to 30-amino acid residue peptide comprising an amino acid sequence represented by the following formula (I): X | 07-26-2012 |
20120214742 | GABA RELEASE-REGULATING AGENT IN CEREBELLUM - A GABA (gamma-aminobutyric acid) release-inhibiting agent in the cerebellum and a composition for treating pathological symptoms caused by over-release of GABA in the cerebellum, each comprising a Bestrophin 1(Best1) channel inhibitor as an active ingredient; a GABA release-promoting agent in the cerebellum and a composition for treating pathological symptoms caused by the deficit of GABA in the cerebellum, each comprising a Best1 channel activator as an active ingredient; and a method for screening a GABA release-regulating agent in the cerebellum, which uses Best1 channel as target, are provided. | 08-23-2012 |
20120220534 | BIOMARKER FOR NEURODEGENERATION IN NEUROLOGICAL DISEASE - The present invention provides a method of detecting or diagnosing a neurodegenerative disease or condition in a subject. Further aspects of the invention provide a method of monitoring a subject over a period of time to detect the development or progress of a neurodegenerative disease or condition. Methods of treating, detecting or diagnosing a neurodegenerative disease or condition in a subject are also provided. | 08-30-2012 |
20120225822 | PEPTIDES FOR THE TREATMENT OF OXIDATIVE STRESS RELATED DISORDERS - Isolated DJ-1 related peptides are disclosed and pharmaceutical compositions comprising same for treating oxidative stress-related disorder. | 09-06-2012 |
20120232016 | METHOD AND SYSTEM TO DETECT AND DIAGNOSE ALZHEIMER'S DISEASE - Various embodiments provide methods for the detection, the diagnosis, and/or the prediction of disease onset of Alzheimer's disease. Methods for determining a state of Alzheimer's disease are provided. Accordingly, these methods can comprise the steps of placing a sample comprising at least one blood component onto a substrate, labeling the sample to identify at least one epigenetic marker and at least one of an inflammation marker and a cellular stress marker; determining an amount of the markers; performing a multivariate statistical analysis to produce an output value; comparing the output value to a reference value; and determining a state of Alzheimer's disease. | 09-13-2012 |
20120270795 | COMPOUNDS FOR THE TREATMENT OF DISEASES RELATED TO PROTEIN MISFOLDING - The present invention relates to the field of protein misfolding diseases and thus to diseases which are associated with or induced by abnormal or pathogenic three-dimensional folding of proteins and/or peptides or which are linked to pathogenic conformational changes of proteins and/or peptides, such as Alzheimer's disease. Particularly, the present invention provides novel trimeric pyrazole compounds, which exhibit a therapeutic effectiveness in regard to the aforementioned protein misfolding diseases, and refers to their use for the treatment of such protein misfolding diseases, especially neurodegenerative diseases as well as to medicaments or pharmaceutical compositions comprising these compounds. | 10-25-2012 |
20130059788 | PRODOMAIN MODULATORS OF ADAM 10 - The presently disclosed subject matter discloses isolated ADAM 10 modulating peptides and related compounds useful for studying the biological functions of ADAM 10 and for the treatment of diseases such as cancer, neurological disorders, asthma, and allergic responses, and disorders characterized at least in part by the presence of one or more of inflammation, excess cell proliferation, angiogenesis, and excess soluble CD23. In one aspect, the presently disclosed subject matter provides isolated mouse and human ADAM 10 prodomain comprising the sequence set forth in SEQ ID NOs 1-8, or a sequence having at least 95% homology to any of SEQ ID NOs 1-8 and having the functionality of modulating ADAM 10 activity. | 03-07-2013 |
20130065834 | MODULATORS OF PROTEASOME ACTIVITY - Methods of modulating proteasome activity, increasing life span and neurogenesis are provided herein. | 03-14-2013 |
20130102539 | PEPTOIDS AND METHODS FOR TREATING ALZHEIMER'S DISEASE - Provided herein are peptoids capable of inhibiting or reversing amyloid β (Aβ) fibril or plaque production. The peptoids form a helical structure with three monomers per helical turn and have at least two monomers with a side-chain having an arylalkyl group having the same chirality positioned such that the side-chains are on the same side of the peptoid. Also provided are methods of using the peptoids to inhibit or reverse aggregation of Aβ and methods of treating subjects with Alzheimer's disease (AD) or slowing the progression of AD. | 04-25-2013 |
20130116192 | N-(AMINOACYL)-AMINO COMPOUND - N-(aminoacyl)-amino compound, represented by the following formula | 05-09-2013 |
20130116193 | USE OF THE PAT NONAPEPTIDE IN TREATING AND PREVENTING NEURODEGENERATIVE DISEASES - The invention relates to the use of the PAT nonapeptide in the manufacture of a drug for preventing or treating a neurodegenerative disease such as Alzheimer's disease. The parenteral route of administration is preferable, including the subcutaneous, intraperitoneal, intravenous or intranasal routes. The invention also relates to an injectable formulation containing the PAT nonapeptide which can be administered to patients suffering from a neurodegenerative disease such as Alzheimer's disease. | 05-09-2013 |
20130123188 | METHODS FOR DIAGNOSING AND TREATING ALZHEIMER'S DISEASE (AD) USING THE MOLECULES THAT STABILIZE INTRACELLULAR CALCIUM (Ca2+) - The subject technology relates, in part, to a method of treating Alzheimer's Disease (AD), early-stage AD, elevated risk of AD, mild cognitive impairment (MCI), or other forms of age-related cognitive decline in a subject in need thereof by administering to the subject a molecule that promotes calcium-release stabilization in ryanodine receptors (RyRs) and/or inosital triphosphate receptors (InsP3Rs) in brain cells. Diagnostic methods using calcium-release stabilizing immunophilins, junctophilins or calmodulin are also disclosed. | 05-16-2013 |
20130143822 | AGENTS FOR TREATING ALZHEIMER'S DISEASE - Agents for treating Alzheimer's disease comprising a peptide according to sequence no. 1 which binds to Aβ oligomers and thus results in the healing or alleviation of Alzheimer's disease. In further embodiments peptides are provided which contain a sequence no. 1, but have preceding sequence sections which allow the peptide to be secreted. For the purpose of gene therapy, corresponding DNA sequences and vectors, in particular according to sequences 3 to 6, are provided. | 06-06-2013 |
20130172262 | COMPOUND AND METHOD FOR TREATMENT OF ALZHEIMER'S DISEASE AND FAMILIAL DEMENTIA - An isolated protein is provided for use in treatment of a condition selected from the group consisting of Alzheimer's disease, familial Danish dementia and familial British dementia in a mammal, including man. The isolated protein is selected from the group consisting of proteins comprising an amino acid sequence having at least 70% identity to residues 90-236 of Bri2 from human; and proteins comprising an amino acid sequence having at least 70% identity to any one of the Brichos domains of Bri2 from human, chimpanzee, bovine, pig, mouse and rat. | 07-04-2013 |
20130225498 | COMPOSITION FOR PREVENTING OR TREATING NEURODEGENERATIVE DISEASES CONTAINING CCL5 - There is provided a composition for preventing or treating neurodegenerative diseases, including one or two or more selected from the group consisting of a chemoattractant CCL5, a CCL5 expression regulator, and a CCL5 activator as an active ingredient, in which by confirming through a morris water maze task that the CCL5 recovers memory loss and improves spatial cognition ability, it has been found that the composition including any one or two or more selected from the group consisting of the CCL5, the CCL5 expression regulator, and the CCL5 activator can be usefully employed as a pharmaceutical composition or a food composition for preventing or treating neurodegenerative diseases. | 08-29-2013 |
20130231290 | METHODS OF DIAGNOSING AND TREATING NEURODEGENERATIVE DISEASES - The present invention relates to methods of diagnosing, treating and prognosing mental disorders, such as Alzheimer's Disease. In one embodiment, the present invention provides a method of treating Alzheimer's Disease by inhibiting dysfunctional signaling of α7 nAChRs in the medial septum region of an individual. | 09-05-2013 |
20130244946 | COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF NEURODEGENERATIVE DISEASES - Isolated peptides are provided, being less than 20 amino acids in length. The peptides comprising an amino acid sequence GVLYVGSKTREGV (SEQ ID NO: 12) AAATGLVKREE (SEQ ID NO: 13) or GVVAAAEKTKQG (SEQ ID NO: 14), mimetics and/or fragment thereof, the peptides being capable of inhibiting alpha synuclein aggregation. Pharmaceutical compositions comprising same are also provided as well as uses thereof. | 09-19-2013 |
20130252901 | PEPTIDE COMPOUND USEFUL FOR INHIBITING AMYLOID PLAQUE FORMATION - A peptide compound of the following general formula (I) or (II): | 09-26-2013 |
20130316955 | AMINOSTATIN DERIVATIVES FOR THE TREATMENT OF ARTHROSIS - The present invention relates to compounds of the formula (I) and in particular medicaments comprising at least one compound of the formula (I) for use in the treatment and/or prophylaxis of physiological and/or pathophysiological states in the triggering of which cathepsin D is involved, in particular for use in the treatment and/or prophylaxis of arthrosis, traumatic cartilage injuries, arthritis, pain, allodynia or hyperalgesia. | 11-28-2013 |
20130331330 | METHODS OF TREATING ALZHEIMER'S DISEASE AND OTHER TAUOPATHIES WITH INHIBITORS OF MICROTUBULE AFFINITY REGULATING KINASE - Methods of treating Alzheimer's disease and other tauopathies are disclosed. In particular, the invention relates to methods of treating Alzheimer's disease and other tauopathies with inhibitors of microtubule affinity regulating kinase (MARK). Hyperphosphorylation of tau by MARK is associated with the pathogenic deposition of intracellular neurofibrillary tangles and loss of synaptic markers, dendritic spines, and synapses during progression of Alzheimer's disease and other tauopathies. Peptide inhibitors derived from the | 12-12-2013 |
20130338075 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF AXONAL AND NEURONAL DEGENERATION - The present invention generally relates to methods and compositions for preventing or treating axonal and/or neuronal degeneration in a subject by administering a composition comprising a peptide that comprises the amino acid sequence Arginine-Glycine-Aspartate (RGD). | 12-19-2013 |
20130338076 | PEPTIDES AND METHODS USING SAME FOR DIAGNOSIS AND TREATMENT OF AMYLOID-ASSOCIATED DISEASE - Peptides having at least 2 amino acids and no more than 15 amino acids are provided. The peptides comprise amino acid sequence X-Y or Y-X, wherein X is an aromatic amino acid and Y is any amino acid other than glycine. Also provided are pharmaceutical compositions and kits including such peptides as well as methods using same for diagnosing and treating amyloid associated diseases. | 12-19-2013 |
20130345142 | DETECTING AND TREATING DEMENTIA - This document relates to methods and materials for detecting mutations that can be linked to dementia. For example, methods and materials for detecting one or more mutations within PGRN nucleic acid are provided. This document also provides methods and materials for detecting the level of progranulin expression. In addition, this document relates to methods and materials for treating mammals having a neurodegenerative disorder (e.g., dementia). For example, methods and materials for increasing PGRN polypeptide levels in mammals are provided, as are methods and materials for identifying agents that can be used to increase PGRN polypeptide levels in mammals. | 12-26-2013 |
20140011744 | Method for Regulating Neurite Growth - This invention relates to a method of inhibiting neuronal cell death, including protecting neuronal cells from cell death and the effects of stress, such as high or low pH, comprising administering to the cells an effective amount of Teneurin C-terminal Associated Peptide (TCAP). The invention provides the use of TCAP to prevent and/or treat a number of brain conditions, such as hypoxia-ischemia and brain alkalosis or various brain or spinal cord injuries due to physical or physiological stresses. In one aspect the invention provides a use of TCAP to increase β-tubulin, β-actin levels in neuronal cells and/or to increase fasciculation among neuronal cells, in culture or in tissue. In another aspect, the invention provides a method of treating various pH induced neuronal conditions. | 01-09-2014 |
20140018300 | NEUROPROTECTIVE AND NEURORESTORATIVE METHODS AND COMPOSITIONS - The invention relates to methods and products for preventing and treating neuronal cell death-associated diseases and/or conditions. The products and methods are useful for research and for clinical applications relating to neuronal cell-death associated diseases and/or conditions. | 01-16-2014 |
20140038898 | PEPTIDES FOR SUPPRESSING INFLAMMATION - Provided herein are peptides that exhibit ApoE biological activity, as well as compositions and pharmaceutical formulations that include the peptides. The peptides, compositions, and methods disclosed herein have broad applications as they can be used to treat a broad spectrum of injury, diseases, disorders, and clinical indications. | 02-06-2014 |
20140045764 | NEUROPROTECTIVE PEPTIDES - A method of treating a neurodegenerative disorder is disclosed. The method comprises administering to the subject a therapeutically effective amount of an isolated peptide comprising at least 3 amino acids of a CD44V10 amino acid sequence no more than 20 amino acids of said CD44V10 amino acid sequence and comprising a neuroprotective activity. | 02-13-2014 |
20140051637 | BRAIN-TARGETING FUNCTIONAL NUCLEIC ACID AND USE THEREOF - The purpose of the invention is to provide a novel therapeutic agent for Alzheimer's disease and use thereof. Provided is a therapeutic agent for Alzheimer's disease, which contains a CpG oligodeoxynucleotide structure having a brain migration and improved stability or a salt thereof as an active ingredient. | 02-20-2014 |
20140094414 | COMPOSITION FOR PREVENTING OR TREATING NEURODEGENERATIVE DISEASE INCLUDING BIOACTIVE PEPTIDE AS EFFECTIVE COMPONENT - There is provided a new use of protein hydrolysates and peptide derived from seahorses for preventing or treating a neurodegenerative disease, and more particularly a composition and health functional foods for preventing or treating a neurodegenerative disease including seahorse protein hydrolysates or peptide isolated and purified from the same as an effective component. | 04-03-2014 |
20140171372 | Treatments for Alzheimer's disease - New Treatments for Alzheimer's Disease utilizing gangliosides, glycoproteins, and replacement of non-mutant enzymes and chaperones, as well as enzyme up-regulation accomplished by a number of gene-therapy methodologies. | 06-19-2014 |
20140171373 | COMPOSITIONS AND METHODS RELATED TO TAUOPATHY - Disclosed herein are isolated polypeptides, antibody preparations, treatment methods, diagnostic methods, and screening methods related to tauopathy. Generally, the isolated polypeptide includes a core pentapeptide, with the proviso that the isolated polypeptide is not a native full-length tau protein. Generally, the antibody preparations include antibody that specifically binds to SEQ ID NO:12. Generally, the treatment methods include administering to a subject a composition that includes the isolated polypeptide. Generally, the diagnostic methods includes contacting a sample from a subject with an antibody preparation that includes antibody that specifically binds to SEQ ID NO:12, and then detecting a ligand in the sample that specifically binds the antibody preparation. Generally, the screening method includes incubating a mixture of caspase-2, a labeled caspase-2 cleavage substrate, and a test compound under conditions effective to permit the caspase-2 to cleave the caspase-2 cleavage substrate, then determining whether the test compound inhibits cleavage of the substrate by caspase-2. | 06-19-2014 |
20140288005 | COMPOUND FOR TREATMENT OF ALZHEIMER'S DISEASE AND FAMILIAL DEMENTIA - An isolated protein is provided for use in treatment of a condition selected from the group consisting of Alzheimer's disease, familial Danish dementia and familial British dementia in a mammal, including man. The isolated protein is selected from the group consisting of proteins comprising an amino acid sequence having at least 70% identity to residues 90-236 of Bri2 from human; and proteins comprising an amino acid sequence having at least 70% identity to any one of the Brichos domains of Bri2 from human, chimpanzee, bovine, pig, mouse and rat. | 09-25-2014 |
20140296153 | Oligodendrocyte Differentiation - The present invention provides compounds, compositions and methods for treatment and/or prevention of neurodegenerative diseases, including but not limited to autoimmune diseases, such as multiple sclerosis, in which demyelination, (the loss of the myelin sheath that insulates the nerves) is an associated or causative feature. The data provided demonstrate the utility of the compounds and compositions according to this invention to promote oligodendrogenesis and myelination or remyelination. | 10-02-2014 |
20140315823 | PEPTIDE COMPOUNDS FOR SUPPRESSING INFLAMMATION - Provided herein are peptides that exhibit ApoE biological activity, as well as compositions and pharmaceutical formulations that include the peptides. The peptides, compositions, and methods disclosed herein have broad applications as they can be used to treat a broad spectrum of injury, diseases, disorders, and clinical indications. | 10-23-2014 |
20140371152 | AMYLOID BETA-PROTEIN-SPECIFIC PRODUCTION-INHIBITING POLYPEPTIDE - A primary object of the present invention is to develop a compound that specifically inhibits the production of Aβ protein and serves as an active ingredient of a drug to treat and/or prevent Alzheimer's disease. | 12-18-2014 |
20150025014 | Treatment of Amyloidoses Using Myelin Basic Protein and Fragments Thereof - In its various embodiments, the invention provides myelin basic proteins and fragments of that interfere with the fibrillization of peptides implicated in the amyloidoses, especially the amyloid-b eta peptide associated with Alzheimer's disease (“AD”) and cerebral amyloid angiopathy (“CAA”). Some embodiments provide methods of identifying additional interfering fragments. Others provide methods of identifying substances that modulate the interference. Further embodiments provide methods of preventing amyloidoses, especially AD and CAA by administering myelin basic proteins or fragments thereof. | 01-22-2015 |
20150038426 | Monomeric and Dimeric Forms of Adiponectin Receptor Fragments and Methods of Use - Methods are disclosed for determining progression of a condition, onset of a condition, or efficacy of treatment of a condition characterized by an adipocyte imbalance in a patient. In addition, disclosed herein are methods of treating diabetes, abnormal adipocyte activity, and insulin resistance using monomeric, homodimeric, and heterodimeric forms of certain C-terminal fragments of adiponectin receptor. In addition, methods of treating abnormal adipocyte activity, treating metabolic syndrome, causing insulin secretion, increasing insulin levels, inhibiting insulin degradation enzyme, treating Alzheimer's disease, treating cardiovascular disease associated with adiponectin levels, inhibiting ADAM-17 enzyme, inhibiting a protease, treating a condition associated with TNF-alpha, and treating a condition associated with HER | 02-05-2015 |
20150119336 | POLYMERS CONTAINING MULTIVALENT AMYLOID-BETA-BINDING D-PEPTIDES AND THEIR USE - The invention relates to novel multivalent polymeric amyloid-beta-binding substances composed of several interconnected substances which per se already have amyloid-beta-binding properties, and to the use of these substances, referred to hereinbelow as “polymers”, in particular in medicine. | 04-30-2015 |
20150133388 | ACETYLATED CRYSTALLIN POLYPEPTIDES AND MIMETICS THEREOF AS THERAPEUTIC AGENTS - A method of inhibiting, reducing, and/or treating pathological apoptosis and/or protein aggregation in a subject includes administering to the subject an amount of a therapeutic polypeptide effective to inhibit, reduce, and/or treat the pathological apoptosis and/or protein aggregation. The therapeutic polypeptide including at least one of acetylated αA-crystallin, acetylated αB-crystallin, acetylated fragments thereof having molecular chaperone activity, and/or polypeptide mimetics thereof that can inhibit pathological protein aggregation and/or pathological apoptosis. | 05-14-2015 |
20150299262 | CYCLIC PEPTIDE AND PHARMACEUTICAL PRODUCT CONTAINING SAME - Provided is a novel compound which has excellent inhibitory activity for Aβ aggregation, and which is useful as a drug. | 10-22-2015 |
20150307552 | NOVEL D-ENANTIOMERIC PEPTIDES DERIVED FROM D3 AND USE THEREOF - The present invention relates to novel D-enantiomeric A-beta-oligomer-binding peptides, homologs, fragments, parts and polymers thereof and use thereof. | 10-29-2015 |
20150328281 | NOVEL ENTERIC COMBINATION THERAPY - There is disclosed herein a composition for treating gastrointestinal or neurological disorders, constipation, functional constipation, irritable bowel syndrome, diverticulitis, travelers diarrhoea, chronic idiopathic nausea, IBD-associated constipation and diarrhoea, pseudo-obstruction, diabetic gastroparesis, cyclic vomiting, reflux oesophagitis, autism enteropathy, flatulence, halitosis, chronic fatigue, bloating, proctalgia fugax, Parkinsons disease, MS, Alzheimers Disease, Motor Neurone Disease or autism, the composition comprising: (i) at least two anti-clostridial agents selected from the group consisting of: vancomycin, vancomycin derivatives, a multi-valent polymer of vancomycin, aminoglycosides, nitroimidazoles, ansamysins, nifuroxazide, colchicine, prucalopride, prokinetic agent and 5-aminosalicylic acid; or (ii) at least one anti-clostridial agent selected from the above combined with an opioid blocking agent. There is also disclosed herein a method of treating various gastrointestinal or neurological disorders, constipation, functional constipation, irritable bowel syndrome, diverticulitis, travelers diarrhoea, chronic idiopathic nausea, IBD-associated constipation and diarrhoea, pseudo-obstruction, diabetic gastroparesis, cyclic vomiting, reflux oesophagitis, autism enteropathy, flatulence, halitosis, chronic fatigue, bloating, proctalgia fugax, Parkinsons disease, MS, Alzheimers Disease, Motor Neurone Disease or autism, the method comprising administering orally, via enema or by suppository: (i) a composition of the invention; (ii) at least two anti-clostridial agents selected from the group consisting of: vancomycin, vancomycin derivatives, a multi-valent polymer of vancomycin, aminoglycosides, nitroimidazoles, ansamysins, nifuroxazide, colchicine, prucalopride, prokinetic agent and 5-aminosalicylic acid; or (iii) at least one anti-clostridial agent selected from the above and an opioid blocking agent to a patient in need of such treatment. | 11-19-2015 |
20150359849 | METHODS OF INCREASING NEURONAL CONNECTIVITY AND/OR TREATING A NEURODEGENERATIVE CONDITION - The inventions provided herein relate to methods, and compositions for increasing neuronal connectivity, neuronal survival and/or axonal growth of a population of neural cells in vitro, ex vivo or in vivo. For in vivo applications, in some embodiments, the methods and compositions described herein can be used to treat cognitive, motor and/or sensory function impairment and/or neurodegeneration in a subject or particularly a human subject {e.g., a human subject who is diagnosed as having, or having a risk, for a neurodegenerative and/or neurological condition such as Alzheimer's disease). Methods for determining a risk for a neurodegenerative condition or disorder, e.g., Alzheimer's disease, in a subject {e.g., a human subject) are also provided herein. | 12-17-2015 |
20160000770 | PHARMACEUTICAL COMPOUNDS AND USE OF SAME IN CANCER AND TAUOPATHIES - Disclosed are compounds of formula (1)-(V): where the substituents are as provided herein. Further disclosed are methods of inhibiting tau aggregation, treating or ameliorating a tauopathy or cancer by administration of such a compound. Tau is a microtubule-binding protein that accumulates in a number of neurodegenerative disorders, including frontotemporal dementia and Alzheimer's disease (AD). The presence of abnormal tau correlates with neuron loss and memory deficits in patients with AD and other neurodegenerative disorders that involve tau accumulation. | 01-07-2016 |
20160002725 | USE OF TRPC6 MRNA LEVELS IN PERIPHERAL BLOOD CELLS FOR EARLY DETECTION/DIAGNOSIS OF SENILE DEMENTIA - The invention relates to the use of TRPC6 mRNA levels in peripheral blood cells for the early detection/diagnosis of senile dementia. Specifically, the present invention provides a classic transient receptor potential channel 6 (TRPC6) gene or protein thereof and the use of same in preparing a reagent or test kit for detecting or diagnosing Alzheimer's disease. The present invention further relates to a polypeptide used to prepare a medicament that treats AD, and relates to a composition of said polypeptide. | 01-07-2016 |
20160030510 | METHODS OF TREATING ALZHEIMER'S DISEASE AND OTHER TAUOPATHIES WITH INHIBITORS OF MICROTUBULE AFFINITY REGULATING KINASE - Methods of treating Alzheimer's disease and other tauopathies are disclosed. In particular, the invention relates to methods of treating Alzheimer's disease and other tauopathies with inhibitors of microtubule affinity regulating kinase (MARK). Hyperphosphorylation of tau by MARK is associated with the pathogenic deposition of intracellular neurofibrillary tangles and loss of synaptic markers, dendritic spines, and synapses during progression of Alzheimer's disease and other tauopathies. Peptide inhibitors derived from the | 02-04-2016 |
20160052980 | CRP40 FRAGMENTS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS - Disclosed herein are human CRP40 fragments and polynucleotides encoding them. The CRP40 fragments and polynucleotides may be useful in the treatment of diseases associated with one or more of oxidative stress, mitochondrial dysfunction and abnormal protein folding, including various neurological disorders. | 02-25-2016 |
20160074463 | USE OF THE PAT NONAPEPTIDE IN THE TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES - A PAT nonapeptide of formula EAKSQGGSD can be used to treat or prevent neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Huntington's disease and amyotrophic lateral sclerosis. Pharmaceutical compositions containing the PAT nonapeptide can be formulated for administration by parenteral route, including the subcutaneous, intraperitoneal, intravenous or intranasal routes. | 03-17-2016 |
20160108093 | CYCLIZED TRANSTHYRETIN PEPTIDE AND METHODS OF USE THEREFOR - The present disclosure describes cyclized peptides that inhibit Aβ toxicity and therefore can be used as therapeutic agents to treat Alzheimer's Disease. | 04-21-2016 |
20160115208 | USE OF AN IMMUNOMODULATORY PROTEIN FROM GANODERMA IN PROMOTING NEURITE OUTGROWTH - The inventors surprisingly found that an immunomodulatory protein from | 04-28-2016 |
20160122403 | GHRELIN SPLICE VARIANT FOR TREATING NEURONAL DAMAGE,NEURODEGENERATIVE DISEASE, PARKINSONS DISEASE, ALZHEIMERS DISEASE, AND/OR DEPRESSION - The present disclosure relates, in one aspect, to use of ghrelin splice variant or an analogue thereof, or a ghrelin splice variant-like compound for the preparation of a medicament for one or more of: treatment and/or prevention of neuronal damage and/or neurodegeneration and, prophylaxis or treatment of neuronal damage and/or neurodegenerative disease, Parkinson's disease, Alzheimer's disease, depression stimulation of neuronal activity. A further aspect relates to a number of new ghrelin splice variant-like compounds and uses thereof, as well as to pharmaceutical compositions and medical packaging comprising the new ghrelin splice variant-like compounds. | 05-05-2016 |
20160137706 | OXIDIZED A BETA PEPTIDE - The invention provides an Aβ peptide aggregation inhibitor, an Aβ peptide toxicity reducing agent, and a preventive and/or therapeutic agent for Alzheimer's disease. The oxidized Aβ peptide in which one or more amino acid residues of Aβ peptide have been oxidized (excluding an oxidized Aβ peptide in which only Met has been oxidized). | 05-19-2016 |
20160168212 | COMPOSITIONS FOR TREATMENT OF NEURODEGENERATIVE DISEASES | 06-16-2016 |
20160184397 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND/OR PREVENTION OF DISEASE INVOLVING ABNORMAL ACCUMULATION OF AMYLOID BETA PROTEIN - Disclosed is a pharmaceutical composition for the treatment and/or prevention of a disease involving abnormal accumulation of amyloid β protein comprising ILEI, or a vector into which a polynucleotide encoding ILEI is inserted; a method for screening a compound for the treatment and/or prevention of a disease involving abnormal accumulation of amyloid β protein; and a method for treating and/or preventing a disease involving abnormal accumulation of amyloid β protein. | 06-30-2016 |
20160193279 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF AXONAL AND NEURONAL DEGENERATION | 07-07-2016 |
20160251665 | CELLS EXPRESSING APOLIPOPROTEIN E AND USES THEREOF | 09-01-2016 |
20160375088 | CARDIOLIPIN-TARGETED PEPTIDES INHIBIT BETA-AMYLOID OLIGOMER TOXICITY - The present disclosure provides aromatic-cationic peptides and methods of using the same. The methods comprise the use of the aromatic-cationic peptides in reducing the effects of toxic beta amyloid (Aβ) peptides including blocking the accumulation of extracellular Aβ oligomers, inhibiting Aβ-mediated oxygenase activity, reducing Aβ-induced mitochondrial dysfunction and/or preventing Aβ-induced neuronal apoptosis. | 12-29-2016 |
20160376311 | PEPTOIDS AND METHODS FOR TREATING ALZHEIMER'S DISEASE - Provided herein are peptoids capable of inhibiting or reversing amyloid β (Aβ) fibril or plaque production. The peptoids form a helical structure with three monomers per helical turn and have at least four monomers with a side-chain having an arylalkyl or aryl group. The peptoid may be achiral. Also provided are methods of using the peptoids to inhibit or reverse aggregation of Aβ and methods of treating subjects with Alzheimer's disease (AD) or slowing the progression of AD. | 12-29-2016 |
20160376335 | POLYMERS CONTAINING MULTIVALENT AMYLOID-BETA-BINDING D-PEPTIDES AND THEIR USE - The invention relates to novel multivalent polymeric amyloid-beta-binding substances composed of several interconnected substances which per se already have amyloid-beta-binding properties, and to the use of these substances, referred to hereinbelow as “polymers”, in particular in medicine. | 12-29-2016 |
20170232055 | METHODS OF SYNTHESIZING GAMMA-AAPEPTIDES, GAMMA-AAPEPTIDE BUILDING BLOCKS, GAMMA-AAPEPTIDE LIBRARIES, AND GAMMA-AAPEPTIDE INHIBITORS OF ALPHA-BETA40 AGGREGATES | 08-17-2017 |